Glass in Vials Leads to Recall of Several Hospira Products

News
Article

The presence of glass can lead to serious adverse events, including inflammation of a vein and blockage of blood vessels or life-threatening blood clots.

Hospira is recalling several products because glass particulates were found during product inspection. The presence of glass can lead to serious adverse events, including inflammation of a vein, granuloma, and blockage of blood vessels or life-threatening blood clots.

This recall impacts:

  • Bleomycin for Injection, single dose with ONCO-TAIN glass fliptop vial, lot number BL12206A and NDC 61703-332-18. It has an expiration date of June 30, 2024. Bleomycin is used to treat several types of cancer, including head and neck, uterine, cervical, testicular, and lymphoma.
  • 4.2% Sodium Biocarbonate Injection, with ABBOJECT glass syringe, lot number GX1542, with NDC for the carton 0409-5534-24 and NDC for the case 0409-5534-14. It has an expiration date of Jan. 1, 2025. It is indicated to treat patients with metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, severe dehydration, , cardiac arrest and severe primary lactic acidosis.
  • 8.4% Sodium Biocarbonate Injection, with Lifeshield ABBOJECT glass syringe, lot number HA7295 with NDC for the carton 0409-6637-24 and NDC for the case 0409-6637-14. It has an expiration of March 1, 2025.
  • Atropine Sulfate Injection, with Lifeshield ABBOJECT glass syringe, lot number of GY2496 with NDC for the carton 0409-4911-11 and NDC for the case 0409-4911-34. It has an expiration of Feb. 1, 2025. It blocks severe or life-threatening muscarinic effects.

To date, Hospira has not received reports of any adverse events associated with these products.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.